Journal article icon

Journal article

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data

Abstract:

Background

Patients with type 2 diabetes mellitus (T2DM) have elevated cardiovascular risk. PCSK9 monoclonal antibodies have been shown to reduce LDL-C and other lipids, but specific efficacy for patients with diabetes is unknown.

Methods

We studied the effect of the PCSK9 inhibitor evolocumab on lipid parameters (LDL-C, non-HDL-cholesterol, total cholesterol, triglycerides, lipoprotein(a), HDL-C) in patients with and without T2DM. We searched Medline and EMBASE (2...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Nuffield Department of Population Health
Sub department:
Clinical Trial Service Unit
Role:
Author
Publisher:
Elsevier
Journal:
Lancet Diabetes and Endocrinology More from this journal
Publication date:
2016-02-01
DOI:
ISSN:
2213-8587
Pubs id:
pubs:602508
UUID:
uuid:fb4654a6-04d2-4372-b6b9-074a7f4ed9c6
Local pid:
pubs:602508
Source identifiers:
602508
Deposit date:
2016-02-15

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP